Xeris Biopharma Holdings Analyst Ratings
Xeris Biopharma Holdings Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 227.38% | HC Wainwright & Co. | $6 → $5.5 | Maintains | Buy |
| 11/10/2023 | 138.1% | Piper Sandler | $5 → $4 | Maintains | Overweight |
| 08/28/2023 | 167.86% | Craig-Hallum | → $4.5 | Initiates Coverage On | → Buy |
| 08/09/2023 | 257.14% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/10/2023 | 257.14% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/09/2023 | 257.14% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 01/27/2023 | 197.62% | SVB Leerink | $6 → $5 | Maintains | Outperform |
| 10/21/2022 | 138.1% | Jefferies | → $4 | Assumes | → Buy |
| 04/28/2022 | 286.9% | Craig-Hallum | → $6.5 | Initiates Coverage On | → Buy |
| 03/16/2022 | 257.14% | Mizuho | $8 → $6 | Maintains | Buy |
| 02/16/2022 | 257.14% | SVB Leerink | $8 → $6 | Maintains | Outperform |
| 12/31/2021 | 376.19% | SVB Leerink | $6 → $8 | Maintains | Outperform |
| 12/31/2021 | 221.43% | HC Wainwright & Co. | $4.25 → $5.4 | Maintains | Buy |
| 11/17/2021 | 257.14% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
| 10/29/2021 | 138.1% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 04/23/2020 | 733.33% | Mizuho | $18 → $14 | Maintains | Buy |
| 02/20/2020 | 971.43% | Mizuho | $22 → $18 | Maintains | Buy |
| 02/18/2020 | 614.29% | Piper Sandler | → $12 | Initiates Coverage On | → Overweight |
| 09/11/2019 | 1209.52% | Mizuho | $27 → $22 | Maintains | Buy |
| 日期 | 上行/下行 | 分析师事务所 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/13/2023 | 227.38% | HC Wainwright & Co. | 6 美元 → 5.5 美元 | 维护 | 购买 |
| 11/10/2023 | 138.1% | 派珀·桑德勒 | 5 美元 → 4 美元 | 维护 | 超重 |
| 08/28/2023 | 167.86% | Craig-Hallum | → 4.5 美元 | 启动覆盖范围开启 | → 购买 |
| 08/09/2023 | 257.14% | HC Wainwright & Co. | → 6 美元 | 重申 | 购买 → 购买 |
| 05/10/2023 | 257.14% | HC Wainwright & Co. | → 6 美元 | 重申 | 购买 → 购买 |
| 03/09/2023 | 257.14% | HC Wainwright & Co. | → 6 美元 | 重申 | → 购买 |
| 01/27/2023 | 197.62% | SVB Leerink | 6 美元 → 5 美元 | 维护 | 跑赢大盘 |
| 10/21/2022 | 138.1% | 杰富瑞集团 | → 4 美元 | 假设 | → 购买 |
| 04/28/2022 | 286.9% | Craig-Hallum | → 6.5 美元 | 启动覆盖范围开启 | → 购买 |
| 2022 年 3 月 16 日 | 257.14% | 瑞穗市 | 8 美元 → 6 美元 | 维护 | 购买 |
| 02/16/2022 | 257.14% | SVB Leerink | 8 美元 → 6 美元 | 维护 | 跑赢大盘 |
| 12/31/2021 | 376.19% | SVB Leerink | 6 美元 → 8 美元 | 维护 | 跑赢大盘 |
| 12/31/2021 | 221.43% | HC Wainwright & Co. | 4.25 美元 → 5.4 美元 | 维护 | 购买 |
| 11/17/2021 | 257.14% | SVB Leerink | → 6 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 10/29/2021 | 138.1% | HC Wainwright & Co. | → 4 美元 | 启动覆盖范围开启 | → 购买 |
| 04/23/2020 | 733.33% | 瑞穗市 | 18 美元 → 14 美元 | 维护 | 购买 |
| 02/20/2020 | 971.43% | 瑞穗市 | 22 美元 → 18 美元 | 维护 | 购买 |
| 02/18/2020 | 614.29% | 派珀·桑德勒 | → 12 美元 | 启动覆盖范围开启 | → 超重 |
| 09/11/2019 | 1209.52% | 瑞穗市 | 27 美元 → 22 美元 | 维护 | 购买 |
What is the target price for Xeris Biopharma Holdings (XERS)?
Xeris Biopharma Holdings（XERS）的目标价格是多少？
The latest price target for Xeris Biopharma Holdings (NASDAQ: XERS) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $5.50 expecting XERS to rise to within 12 months (a possible 227.38% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月13日公布了Xeris Biopharma Holdings（纳斯达克股票代码：XERS）的最新目标股价。该分析公司将目标股价定为5.50美元，预计XERS将在12个月内上涨至5.50美元（可能上涨227.38％）。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Xeris Biopharma Holdings (XERS)?
Xeris Biopharma Holdings（XERS）的最新分析师评级是多少？
The latest analyst rating for Xeris Biopharma Holdings (NASDAQ: XERS) was provided by HC Wainwright & Co., and Xeris Biopharma Holdings maintained their buy rating.
Xeris Biopharma Holdings（纳斯达克股票代码：XERS）的最新分析师评级由HC Wainwright & Co. 提供，Xeris Biopharma Holdings维持其买入评级。
When is the next analyst rating going to be posted or updated for Xeris Biopharma Holdings (XERS)?
Xeris Biopharma Holdings（XERS）的下一个分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xeris Biopharma Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xeris Biopharma Holdings was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Xeris Biopharma Holdings的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Xeris Biopharma Holdings的最后一次评级是在2023年11月13日提交的，因此您应该预计下一个评级将在2024年11月13日左右公布。
Is the Analyst Rating Xeris Biopharma Holdings (XERS) correct?
分析师评级Xeris Biopharma Holdings（XERS）是否正确？
While ratings are subjective and will change, the latest Xeris Biopharma Holdings (XERS) rating was a maintained with a price target of $6.00 to $5.50. The current price Xeris Biopharma Holdings (XERS) is trading at is $1.68, which is out of the analyst's predicted range.
尽管评级是主观的，并将发生变化，但Xeris生物制药控股公司（XERS）的最新评级维持不变，目标股价为6.00美元至5.50美元。Xeris Biopharma Holdings（XERS）目前的交易价格为1.68美元，超出了分析师的预期区间。